Status: Recruiting
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
This is a randomized trial evaluating the results of using of PD-1 and PD-L1 immune checkpoint inhibitors combined with chemotherapy, with or without bevacizumab, in patients with metastatic, persistent, and recurrent cervical cancer.
Participants needed: 120
Trial details
Phase: Phase 2, Phase 3Age: 18-75Biological sex: FemaleType: InterventionalSponsor: N.N. Alexandrov National Cancer CentreUpdated: May 28, 2026Locations: 1
Eligibility criteria
Age ≥18-≤75 years. [+8]
Presence of another active malignant invasive neoplasm. [+1]